Prognostic value of interim and end of treatment PET-CT scan results in pediatric Hodgkin lymphoma

Introduction: Decision making in refractory colorectal cancer (rCRC) is challenging, with limited data available to predict patient outcome. We conducted a study to assess the pace of cancer progression as a potential prognostic and decision tool. Methods: CORIOLAN was a prospective, single-center, single-arm trial recruiting refractory CRC patients with an ECOG performance status of ≤1 and an estimated life expectancy of ≥12 weeks. 18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) scan and blood sample collection were carried out at baseline and after 2 weeks with no cancer treatment given between these timepoints. The primary objective was to evaluate the association between pace of cancer progression as defined by changes of the whole-body metabolically active tumor volume (WB-MATV) and overall survival (OS). Exploratory objectives included evaluation of the prognostic value of circulating cell-free DNA (cfDNA), circulating tumor cells (CTCs) and carcinoembryonic antigen (CEA). Results: 47 eligible patients who had received a median number of 5 (range 2–8) prior treatments were enrolled. At the time of analysis, 45 deaths had occurred, with 26% of patients dying within 12 weeks. The median OS was 6.3 months (range 0.4–14.3). The median relative delta between WB-MATV at baseline and 2 weeks was +21%. Changes of WB-MATV, however, failed to predict OS (hazard ratio (HR) 1.3, p = 0.383). Similarly, no association was observed between changes of any of the circulating biomarkers investigated and prognosis. By contrast, high WB-MATV (4.2 versus 9.4 months; HR 3.1, p = 0.003), high CEA (4.4 versus 7.0 months; HR 1.9, p = 0.053), high cfDNA (4.7 versus 7.0 months; HR 2.2, p = 0.015) and high CTC count (3.3 versus 7.5 months; HR 6.5, p < 0.001) at baseline were associated with worse OS. Conclusions: In this study, approximately 1 out of 4 refractory CRC patients who were judged to have a life expectancy >12 weeks actually died within 12 weeks. Baseline assessment of WB-MATV, cfDNA, CTCs and CEA, but not early change evaluation of the same, may help to refine patient prognostication and guide management decisions.

Download Full-text

Prognostic value of PET-CT scan on survival outcomes of advanced-staged ovarian cancer patients treated with neoadjuvant chemotherapy: A prospective study

Gynecologic Oncology ◽

10.1016/j.ygyno.2020.05.634 ◽

2020 ◽

Vol 159 ◽

pp. 343

Author(s):

S. Petousis ◽

A.L. Cazeau ◽

A. Crombe ◽

M. Kind ◽

S. Croce ◽

...

Keyword(s):

Ovarian Cancer ◽

Neoadjuvant Chemotherapy ◽

Prospective Study ◽

Ct Scan ◽

Cancer Patients ◽

Prognostic Value ◽

Survival Outcomes ◽

Pet Ct ◽

A Prospective Study ◽

Pet Ct Scan

Download Full-text

Prognostic Value of Interim and End of Treatment FDG-PET/CT Scan Results in Adult Patients with Burkitt Lymphoma - a Retrospective Analysis of a Single Center Cohort

Blood ◽

10.1182/blood.v126.23.5025.5025 ◽

2015 ◽

Vol 126 (23) ◽

pp. 5025-5025

Author(s):

Eldar Priel ◽

Meirav Kedmi ◽

Tima Davidson ◽

Ginette Schiby ◽

Elena Ribakovsky ◽

...

Keyword(s):

Ct Scan ◽

Fdg Pet ◽

Adult Patients ◽

Ct Scans ◽

Survival Outcomes ◽

Interim Pet ◽

End Of Treatment ◽

Pet Ct ◽

Fdg Pet Ct ◽

Pet Ct Scan

Abstract Introduction: End of treatment FDG-PET/CT activity is a powerful predictor of survival outcome in patients with Hodgkin, Diffuse large B cell and Follicular lymphomas. The predictive value of interim PET/CT scan on survival in Hodgkin lymphoma is also well established. To date, there are limited data regarding the prognostic significance of interim and end of treatment FDG-PET/scan results in adult patients with Burkitt lymphoma (BL), mainly due to the rarity of this entity. In this single-center retrospective study we analyzed the survival outcomes of patients with BL according to the findings on interim and end of treatment FDG-PET/CT scans using the Deauville criteria. Methods: We thoroughly reviewed the clinical records of all BL patients who were treated in our medical center between 2005-2014. Thirty three patients and 104 scans were included in our final analysis. Interim PET/CT scan was performed before starting the 3rd cycle of the therapy. PET/CT scans were scored as positive or negative based on the five-point scale: scores 1-3 represented complete metabolic response (CMR) and scores 4-5 defined persistent or progressive disease. Response and survival outcomes were defined according to the Lugano Classification. Survival was calculated with the Kaplan-Meier method and survival comparison was analyzed with the Log-Rank test. Results: Twenty four (73 %) were males and median age was 48 years (22-78). Two patients were HIV positive. Twenty four patients (73%) had stage 3 or 4 disease and 25 patients (76%) had high-intermediate or high risk disease according to the International Prognostic Index. All patients received intensive regimens, and the majority of them (78%) were treated according to the GMALL-B-ALL/NHL2002 protocol. Rituximab was part of treatment in 28 (85%) patients. After a median follow-up of 1.92 years (yrs) (0.08-9.58), 7 patients (21%) have died: six due to advanced BL and one from treatment related toxicity. The overall (OS) and progression-free survival (PFS) at 3-yrs for all patients were 76% and 70%, respectively. Importantly, OS was predicted by the results of end of treatment PET/CT scans: patients in CMR (n=21) had OS of 90% while those with positive PET/CT (n=5) had OS of 30% at 3 years (Figure 1, p=0.001). Early-interim PET/CT results did not predict either PFS or OS at 3 years (OS - 85% for patients in CMR and 60% for patients with positive PET, p=0.27). Conclusions: The current retrospective study indicates that adult patients with BL, who receive rituximab-based intensive regimens, such as the GMALL-B-ALL/NHL2002 protocol, have a favorable outcome. End of treatment PET activity strongly predicted survival outcomes while interim PET result did not correlate with prognosis. Based on our data, it appears that changing treatment in adult patients with BL only on the basis of interim PET/CT results is not advised, unless there is clear evidence of progression. *Authors EP, MK & TD equally contributed to this study. Disclosures No relevant conflicts of interest to declare.

Download Full-text

Prognostic value of SUVmax on 18F-fluorodeoxyglucose PET/CT scan in patients with malignant pleural mesothelioma

PLoS ONE ◽

10.1371/journal.pone.0229299 ◽

2020 ◽

Vol 15 (2) ◽

pp. e0229299 ◽

Cited By ~ 1

Author(s):

Jun Hyeok Lim ◽

Joon Young Choi ◽

Yunjoo Im ◽

Hongseok Yoo ◽

Byung Woo Jhun ◽

...

Keyword(s):

Ct Scan ◽

Malignant Pleural Mesothelioma ◽

Prognostic Value ◽

Pleural Mesothelioma ◽

18F Fluorodeoxyglucose ◽

Pet Ct ◽

Pet Ct Scan ◽

Fluorodeoxyglucose Pet

Download Full-text

Evaluation of Active Disease in a Patient of non-Hodgkin Lymphoma by PET-CT scan over non Significant CT, MRI Findings: a case report

Bangladesh Journal of Nuclear Medicine ◽

10.3329/bjnm.v21i2.40369 ◽

2019 ◽

Vol 21 (2) ◽

pp. 125-128

Author(s):

Abu Bakker Siddique ◽

Mohammad Simoon Salekin ◽

Fatima Begum ◽

Shamim MF Begum

Keyword(s):

Computed Tomography ◽

Ct Scan ◽

Hodgkin Lymphoma ◽

Hybrid Imaging ◽

Imaging Modality ◽

Diagnostic Tools ◽

Non Hodgkin Lymphoma ◽

Pet Ct ◽

Pet Ct Scan ◽

Active Disease

Imaging modalities like computed tomography (CT) and MRI (magnetic resonance imaging) have been used as diagnostic tools for decades for screening as well as staging for any malignancies but these scans provide anatomical information only. After introduction of 18 Flurodeoxyglucose (FDG) positron emission tomography-computed tomography (PET-CT) hybrid imaging modality as molecular imaging technique by measuring glucose metabolism has revolutionized the detection capability of tumor. PET-CT scan has been used in localization and staging of lymphoma for two decades worldwide. Here, a case of 52 years male, diagnosed case of non-Hodgkin lymphoma (NHL) and received chemotherapy. At the end of therapy results of conventional imaging by CT, MRI suggested complete response of the disease. However, simultaneous PET-CT scan showed extensive active disease. PET-CT hybrid imaging provides additive information about location and extent of the active tumor over CT & MRI, which have limitation to define functional lesion. Bangladesh J. Nuclear Med. 21(2): 125-128, July 2018

Download Full-text